Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Liver stiffness measurement (LSM) is recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients with alcohol-related liver disease (ALD).</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">We performed an observational cohort study of compensated patients at risk of ALD from Denmark and Austria. We evaluated the risk of decompensation and all-cause mortality, stratified for compensated advanced chronic liver disease (cACLD: baseline LSM ≥10 kPa) and LSM changes after a median of 2 years. In patients with cACLD, we defined LSM changes as (A) LSM increase ≥20% ("cACLD increasers") and (B) follow-up LSM &lt;10 kPa or &lt;20 kPa with LSM decrease ≥20% ("cACLD decreasers"). In patients without cACLD, we defined follow-up LSM ≥10 kPa as an LSM increase ("No cACLD increasers"). The remaining patients were considered LSM stable.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">We followed 536 patients for 3,008 patient-years, median age 57 years (IQR 49-63), baseline LSM 8.1 kPa (IQR 4.9-21.7). 371 patients (69%) had follow-up LSM after a median of 25 months (IQR 17-38), 41 subsequently decompensated and 55 died. Of 125 with cACLD at baseline, 14% were "cACLD increasers" and 43% "cACLD decreasers", while 13% of patients without cACLD were "No cACLD increasers" (n = 33/246). Baseline LSM, follow-up LSM and LSM changes accurately predicted decompensation (C-index: baseline LSM 0.85; follow-up LSM 0.89; LSM changes 0.85) and mortality (C-index: baseline LSM 0.74; follow-up LSM 0.74; LSM changes 0.70). When compared to "cACLD decreasers", "cACLD increasers" had significantly lower decompensation-free survival and higher risks of decompensation (subdistribution hazard ratio 4.39, p = 0.004) and mortality (hazard ratio 3.22, p = 0.01).</AbstractText>CONCLUSION: <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LSM by transient elastography predicts decompensation and all-cause mortality in patients with compensated ALD both at diagnosis and when used for monitoring.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS" NlmCategory="UNASSIGNED">Patients at risk of alcohol-related liver disease (ALD) are at significant risk of progressive disease and adverse outcomes. Monitoring is essential for optimal disease surveillance and patient guidance, but non-invasive monitoring tools are lacking. In this study we demonstrate that liver stiffness measurement (LSM), using transient elastography, and LSM changes after a median of 2 years, can predict decompensation and all-cause mortality in patients at risk of ALD with and without compensated advanced chronic liver disease. These findings are in line with results from non-alcoholic fatty liver disease, hepatitis C and primary sclerosing cholangitis, and support the clinical utility of LSM, using transient elastography, for disease prognostication and monitoring in chronic liver diseases including ALD, as recommended by the Baveno VII.</AbstractText>

Screening for compensated advanced chronic liver disease using transient elastography in outpatient addiction clinics

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal

Early detection of liver disease in patients with alcohol use disorder improves long-term abstinence

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit

Liver fibrosis screening increases alcohol abstinence

Screening for advanced liver disease incorporating the use of transitional elastography in primary care

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

S1750 Limited Success of Point-of-Care Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Related Fibrosis Using FIB-4/Transient Elastography in a Weight Management/Diabetes Clinic

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population

Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension

Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis

Identify, screen and treat via electronic pathway: a semiautomated approach to retriaging a liver clinic waitlist

Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease

Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients

Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living with HIV and Steatotic Liver Disease

Liver stiffness predicts progression to liver‐related events in patients with chronic liver disease – A cohort study of 14 414 patients

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study

Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population